Bill Bradford. MD, PhD is an advisor and consultant in the biopharmaceutical industry. He has over 20 years of experience in public and private companies, including in executive, product development, medical affairs, and board roles.

Dr. Bradford co-founded Indalo Therapeutics in 2016, a clinical-stage fibrosis company, was on the Board of Directors and served as Chief Medical Officer until 2020. Prior to Indalo, he was Senior Vice President, Clinical Development at InterMune where he successfully developed Esbriet® for Idiopathic Pulmonary Fibrosis and advanced a portfolio of therapeutics in the clinic, including treatments for hepatitis C virus.  Bill has also held product development positions at IntraBiotics and Genentech and was an infectious disease specialist and researcher at University of California San Francisco.

Dr. Bradford graduated cum laude with his B.A. from Williams College, received his M.D. from University of North Carolina School of Medicine and Ph.D. in epidemiology from UC Berkeley, and completed his internal medicine residency and infectious disease fellowship at UCSF.

Toby Maher, MBBS, MSc, PhD is Professor of Clinical Medicine and Director of Interstitial Lung Disease at the Keck School of Medicine of the University of Southern California. Previously he was the British Lung Foundation Chair in Respiratory Research and National Institute for Health Research (NIHR) Clinician Scientist. He was Professor of Interstitial Lung Disease and headed up the Fibrosis Research Group at the National Heart and Lung Institute, Imperial College, London. Prof Maher’s research interests include basic and translational research into idiopathic pulmonary fibrosis, with a major focus on biomarker discovery, early phase clinical trials and the pre-clinical validation of putative targets and compound for the treatment of fibrosing lung disease. Prof. Maher qualified from Southampton Medical School. He trained in Respiratory Medicine at the Royal Brompton Hospital. During his training he gained an MSc in Respiratory Medicine from Imperial College London. In 2005 Dr Maher was awarded a Wellcome Trust Clinical Research Fellowship undertaken at the Centre for Respiratory Research, University College London and culminated in the award of a PhD.

Paul Noble, MD is Professor and Chair of the Department of Medicine, Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine, and Director of the Women’s Guild Lung Institute at Cedars-Sinai Medical Center in Los Angeles, CA. Dr. Noble received his medical degree from New York University School of Medicine, and completed his medical residency and chief residency at the University of California, San Francisco Hospitals. Dr Noble completed his fellowships in Pulmonary and Critical Care at the University of Colorado and the National Jewish Center in Denver. Dr Noble is a physician scientist with an active research laboratory focused on elucidating the basic mechanisms of lung fibrosis. His research laboratory has been funded by the National Institutes of Health for the past twenty years. He has been involved in industry-sponsored clinical trials evaluating new therapies in IPF and participated in both the pirfenidone and nintedanib programs that led to the first FDA approved treatments for IPF. Dr Noble is an elected member of the American Society of Clinical Investigation and American Association of Physicians. He is a Deputy Editor of the Journal of Clinical Investigation.

Matthias Ernst, Ph.D. is the Director of the Olivia Newton-John Cancer Research Institute and Head of the School of Cancer Medicine at La Trobe University. Matthias’ research is focused on mechanisms that lead to the formation of tumors and the exploration of novel strategies to target these mechanisms. His work includes a focus on IL-11 as a therapeutic target to treat colorectal cancer and the role of IL-11 in immunological function and modulation of T cell anti-tumor activity.

Mike Gallatin, Ph.D. is Senior Advisor to Frazier Healthcare Partners and is Co-founder and Director of Inipharm. Mike has over 35 years of experience as a scientist and executive in the biopharma industry. He has co-founded multiple companies, including Mavupharma (acquired by AbbVie), Calistoga Pharmaceuticals (acquired by Gilead Sciences), and Stromedix (acquired by Biogen Idec). Mike served as President of Calistoga and was one of the founding scientists at ICOS Corporation, where he served as VP and Scientific Director. Earlier, Mike developed expertise in the fields of immunology/inflammation and oncology while on the faculty at the Fred Hutchinson Cancer Center. Mike has also been a member of the Scientific Advisory Boards of the Keystone Symposia, Caprion, and the University of Texas Department of Chemistry. Mike received his Ph.D. from the University of Alberta Department of Immunology.

Cory Hogaboam, Ph.D. is Professor of Medicine and Research Scientist in the Women’s Guild Lung Institute in the Department of Medicine at Cedars-Sinai and Adjunct Professor of Pathology at the University of Michigan. Cory’s research is focused on elucidating innate and adaptive immune mechanisms that drive chronic lung diseases such as asthma, hypersensitivity pneumonitis, chronic obstructive pulmonary disease, and idiopathic interstitial pneumonias. He earned a bachelor’s of science in zoology from the University of Calgary and holds a doctorate’s degree in Pharmacology from the same institution. Dr. Hogaboam completed postdoctoral training in Immunology at McMaster University and Pathology at the University of Michigan.

Andrew Nash, Ph.D. is the Chief Scientific Officer of CSL Limited, a leading global biotechnology company with a portfolio of life-saving medicines and vaccines. Andrew has extensive research experience in the areas of immunology and cytokine biology. He leads a large team focused on the discovery and development of new recombinant antibody and protein-based medicines to treat serious human diseases. He has extensive experience in the pharmaceutical / biotechnology sector, including at the CEO level. Dr. Nash completed his Ph.D. in Immunology at the University of Melbourne.